|Videos|December 22, 2022

Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

Author(s)Karim Chamie, MD

Karim Chamie, MD, reviews the currently available adjuvant therapy options for patients with stage II or III MIBC who received a cystectomy, and whether he would have treated the patient in the presented case or referred her to a medical oncologist.

Episodes in this series

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 1 Case 1 Presentation: A 60-Year-Old Woman With Muscle-Invasive Bladder Cancer (MIBC)

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 2 Determining Cisplatin Eligibility for Patients with MIBC

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 3 Available Adjuvant Therapy Options for Patients with Stage II or III MIBC After Previous Cystectomy

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 4 Communication and Follow-Up Strategies After Referring a Patient with MIBC to Medical Oncology

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 5 Case 2 Presentation: A 77-Year-Old Man With MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 6 Unmet Needs and Clinical Challenges in the Management of MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 7 Potential Future Approaches to Neoadjuvant and Adjuvant Immunotherapy for MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

EP. 8 Clinical Pearls for Community Urologists Treating Patients with MIBC

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC

ByHannah Clarke

August 17th 2026

Nima Almassi, MD, highlights long-term data on bladder preservation in MIBC

ByNima Almassi, MD

August 13th 2026

Blue light cystoscopy is tied to higher resource use, not health care cost, in NMIBC

ByHannah Clarke

August 11th 2026

The UroOnc Minute: Navigating BCG Maintenance Therapy in NMIBC, With Mark D. Tyson II, MD, MPH

ByAdam B. Weiner, MD,Mark D. Tyson, MD, MPH

August 7th 2026

Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma

ByHannah Clarke

August 5th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC